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Abstract
Hereditary spastic paraplegias (HSPs) comprise a heterogeneous group of inherited neu-
rodegenerative diseases with the cardinal feature of a length-dependent degeneration of 
corticospinal motor axons. They are classified by their mapped genetic loci, SPG1–SPG78. 
Recently, lysosomal dysfunction is one of the pathomechanism for some autosomal-
recessive HSPs. SPG11 is caused by loss-of-function mutations in the SPG11 gene. Its 
gene product is called spatacsin, which is needed for the recycling of lysosomes from 
autolysosomes. SPG15 is caused by loss-of-function mutation in the ZFYVE26 gene. The 
ZFYVE26 gene encodes spastizin. Mutations in spastizin impair autophagosome mat-
uration and lead to an accumulation of immature autophagosomes. SPG48/KIAA0415 
encodes AP5Z1, known to be a spatacsin and spastizin interactor. Its mutations lead to 
loss of protein or mutated forms of protein with defective autophagy. The TECPR2 is a 
human ATG8-binding protein and positive regulator of autophagy, which plays a key 
role in major adult and pediatric neurodegenerative diseases. Mutations in the lysosomal 
trafficking regulator (LYST) gene have been reported to cause hereditary spastic paraple-
gia. The LYST protein is involved in control of the exocytosis of secretory lysosomes. 
Recently, Drosophila with a gene mutation of an LYST homolog was revealed to exhibit 
impaired autophagy.
Keywords: SPG11, SPG15, SPG48, SPG48, SPG49, Chediak-Higashi syndrome, lysosomal 
trafficking regulator, autophagy
1. Introduction
Lysosomal dysfunction, especially disturbance of the autophagy-lysosomal system, sub-
stantially contributes to the pathodynamics of some major neurodegenerative disorders: 
Alzheimer disease, Parkinson disease, Huntington disease, frontotemporal dementia, 
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amyotrophic lateral sclerosis, bulbospinal muscular atrophy and spinocerebellar ataxia 3, 
hereditary spastic paraplegias (HSPs), and so on [1].
Hereditary spastic paraplegias (HSPs) comprise a heterogeneous group of inherited neuro-
degenerative diseases with the cardinal feature of a length-dependent degeneration of corti-
cospinal motor axons [2]. They are classified by their mapped genetic loci, SPG1–SPG78. To 
date, over 60 causative genes have been identified, transmitted by autosomal-dominant, auto-
somal-recessive (AR), X-linked recessive inheritances, with de novo mutations also described.
Several pathogenic mechanisms of HSPs were suggested by the studies in several causative 
genes for HSP. HSP might result from disruption of the axonal transport of molecules, organ-
elles, and other cargos, which mainly affect the distal parts of motor neurons. Other mecha-
nisms for developing HSP are endoplasmic reticulum formation, membrane trafficking, 
mitochondrial function [3], lipid metabolism, and myelination. Recently, lysosomal dysfunc-
tion is one of the pathomechanism for some autosomal-recessive HSPs: SPG11, SPG15, SPG49, 
SPG78, and HSP with lysosomal trafficking regulator (LYST) gene mutation [4, 5].
2. SPG11
The most prevalent autosomal-recessive (AR) HSP is SPG11. SPG11 is characterized by early 
onset spastic paraplegia with mental impairment and peripheral neuropathy. Brain MRI 
shows thin corpus callosum (TCC) [6] (Figure 1).
Figure 1. Brain MRI findings of the SPG11 patient. (A) Sagittal T1 image showing a thin corpus callosum, especially the 
anterior part. (B) Axial FLAIR image showed subtle ears of the lynx formation at the anterior periventricular portions 
of the lateral ventricles.
Lysosomes - Associated Diseases and Methods to Study Their Function32
There may be upper limb involvement and nystagmus. Some patients additionally pres-
ent with parkinsonism or ataxia. Patients with an amyotrophic lateral sclerosis (ALS)-like 
upper motor neuron-dominant phenotype but with atypically long disease duration and 
absence of TCC or mental impairment (ALS5) had been reported [7]. Moreover, peripheral 
neuropathy-dominant phenotype (Charcot-Marie-Tooth disease like) has been described 
recently [8].
Pathological features of SPG11 in neurons are mainly intracytoplasmic granular lysosome-
like structures in supratentorial areas, and others in subtentorial areas are ubiquitin and p62 
aggregates, observed in amyotrophic lateral sclerosis (ALS), except that they are never labeled 
with anti-TDP-43 or anti-cystatin C [9].
SPG11 is caused by loss-of-function mutations in the KIAA1840 gene on chromosome 15q. 
KIAA1840, encoding spatacsin, is expressed ubiquitously in the nervous system, but most 
prominently in the cerebellum, cerebral cortex, hippocampus, and pineal gland. Its gene prod-
uct is called spatacsin, which is needed for the recycling of lysosomes from autolysosomes, 
a process known as autophagic lysosome reformation (ALR). Loss of spatacsin (or spastizin) 
resulted in the depletion of free lysosomes, which are competent to fuse with autophagosomes, 
and an accumulation of autolysosomes, reflecting a failure in ALR. Moreover, spatacsin and 
spastizin were essential components for the initiation of lysosomal tubulation [10]. Fibroblasts 
prepared from patients with SPG11 have selective enlargement of LAMP1-positive structures, 
though prominent abnormal lysosomal storage was not evident [11].
In spatacsin-null mice, lysosomes are diminished in cortical neurons and Purkinje cells in vivo. 
The decreased number of lysosomes useful for fusion with autophagosomes damages autoly-
sosomal clearance, results in the accumulation of undegraded substances, and finally causes 
death of particularly susceptible neurons like cortical motor neurons and Purkinje cells in 
knockout mice [12].
3. SPG15
SPG15 is the second most common type of hereditary spastic paraplegia with thin corpus cal-
losum. SPG15 cases show similar symptoms to those observed in SPG11. Clinical manifesta-
tion in addition to spastic paraplegia includes intellectual disability, pigmentary retinopathy 
(Kjellin syndrome), cerebellar ataxia, parkinsonism, and axonal neuropathy. Brain MRI often 
shows thin corpus callosum.
SPG15, the second most autosomal-recessive HSP, is caused by loss-of-function mutation in 
the ZFYVE26/SPG15 gene. The ZFYVE26 gene encodes a large protein of 2539 amino acid 
residues termed spastizin.
In zebrafish, spastizin, together with spatacsin, is essential for proper establishment of the 
motor neuron axonal network; these proteins are indeed necessary for outgrowth and proper 
targeting of motor neuron axons [13].
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Spastizin interacts with the autophagy-related Beclin 1-UVRAG-Rubicon multiprotein com-
plex and is involved in autophagosome maturation. Mutations in spastizin disrupt its inter-
action with Beclin 1 and thus with the complex, damaging autophagosome maturation and 
resulting in a retention of immature autophagosomes in patient’s fibroblasts. Similarly, a 
deposition of autophagosomes was detected in SHSY5Y cells and in primary hippocampal 
neurons after spastizin silencing, thus indicating that autophagy impairments by spastizin 
deficiency give rise to both neuronal and non-neuronal cells [14].
Spastizin is expressed in the identical organs as spatacsin (SPG11) and partially coexists with 
microtubules, mitochondria, and the nucleus. Spastizin is also observed at the midbody dur-
ing cytokinesis. The spastizin interacts with spatacsin and with KIAA0415 (SPG48), a member 
of the AP5 complex. Mutations lead to loss of protein or mutated forms of protein with defec-
tive autophagy [14].
Zfyve26 knockout mice developed normally by 12 months of age acquire a spastic and ataxic 
gait disorder accompanied by neuron loss in the motor cortex and the cerebellum, consistent 
with the clinical phenotype of SPG15 patients [15]. High-density LAMP1-positive membrane-
bound vesicles and lipopigment accumulate in neurons of Zfyve26 knockout mice [15].
4. SPG48
Two siblings in the one French family have pure adult-onset spastic paraplegia and urinary 
incontinence with hyperintensity of the cervical spinal cord (C3-4,7) in one sibling as the only 
distinguishing magnetic resonance imaging (MRI) feature [16]. Thereafter, clinical features 
included not only prominent spastic paraparesis but also sensory and motor neuropathy, 
ataxia, dystonia, parkinsonism, and myoclonus. Skin fibroblasts from SPG48 patients tested 
positive for periodic acid Schiff (PAS) and intrinsic fluorescence material, while electron 
microscopic analysis indicated lamellar material concordant with abnormal storage of lyso-
somal material [17].
An insertion/deletion mutation has been identified in SPG48/KIAA0415 in two HSP families. 
KIAA0415 encodes a presumptively helicase (AP5Z1), localized in both nucleus and cyto-
plasm, participated in DNA double-strand break repair processes, and interacted with spa-
tacsin and spastizin. Especially, spatacsin is phosphorylated upon DNA damage by protein 
kinases ataxia telangiectasia mutated (ATM) or ATR (ATM and Rad3-related) [16]. A recent 
study showed that the protein is a member of the adaptor protein 5 complex (AP5) that is 
implicated in vesicle formation and sorting (as AP4) [18].
5. SPG49
A homozygous truncating mutation in SPG49/TECPR2 (tectonin beta-propeller repeat con-
taining 2) was identified in a new form of complicated HSP [19]. This HSP is characterized by 
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early onset of spastic paraplegia, motor development delaying, mental retardation, dysmor-
phic features (short stature, round face, low anterior hairline, dental crowding, short broad 
neck, mild brachycephalic microcephaly, a chubby appearance), cerebellar dysarthria, ataxia, 
episodes of central apnea, and TCC on brain MRI.
TECPR2 protein has been established to be a binding partner of the mammalian Atg8 pro-
tein family, including LC3, and a probable positive regulator of autophagosome formation 
[20]. Using fibroblast of affected SPG49 patients and knockdown of TECPR2 using siRNA 
in cultured cell lines, loss of TECPR2 was found to result in a decreased number of autopha-
gosomes and reduced delivery of LC3 and p62 for lysosomal degradation [19]. Recent study 
showed that TECPR2 is involved in maintaining functional endoplasmic reticulum exit sites, 
which may serve as scaffolds for the formation of autophagosomes [21].
6. SPG78
The disease presentation in SPG78 patients was dominated by an adult-onset lower-limb 
predominant spastic paraparesis. Cognitive impairment was present in most of the cases 
and ranged from very mild deficits to advanced dementia with frontotemporal character-
istics. Nerve conduction studies revealed involvement of the peripheral motor and sen-
sory nerves. Only one of five patients with hereditary spastic paraplegia showed clinical 
indication of extrapyramidal involvement in the form of subtle bradykinesia and slight 
resting tremor. Neuroimaging cranial investigations revealed pronounced vermian and 
hemispheric cerebellar atrophy. Notably, reduced striatal dopamine was apparent in the 
brain of one of the patients, who had no clinical signs or symptoms of extrapyramidal 
involvement [22].
ATP13A2, which is causative protein of SPG78, is a lysosomal P5-type transport ATPase, 
the activity of which critically depends on catalytic autophosphorylation. Biochemical and 
immunocytochemical experiments in COS-1 and HeLa cells and SPG78 patient-derived 
fibroblasts demonstrated that the hereditary spastic paraplegia-associated mutations, simi-
larly to the ones causing Kufor-Rakeb syndrome and neuronal ceroid lipofuscinosis, cause 
loss of ATP13A2 function due to transcript or protein instability and abnormal intracellular 
localization of the mutant proteins, ultimately impairing the lysosomal and mitochondrial 
function [22]. They confirm in fibroblast of SPG78 patients that LAMP1-positive organelles 
accumulate, correlating with a reduction in their proteolytic activity. These findings are simi-
lar to that of SPG11 and SPG15 [10, 11, 14]. ATP13A2 has been implicated in autophagy path-
way [23].
7. HSP due to LYST mutation
We encountered an autosomal-recessive (AR) HSP family with cerebellar ataxia and neuropathy 
whose gene locus was not linked to previously reported AR-HSP loci. We have identified a novel 
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homozygous missense mutation in the lysosomal trafficking regulator (LYST) gene, a nuclear gene 
encoding for a protein involved in intracellular trafficking [24]. LYST is described as the caus-
ative gene for Chediak-Higashi syndrome (CHS, OMIM #214500), which is a rare autosomal-
recessive syndrome characterized by hypopigmentation, severe immune-deficiency, a bleeding 
tendency, and progressive neurological dysfunction [25]. We describe a CHS family including 
two patients who show variable degrees of spastic paraplegia, cerebellar ataxia, and neuropa-
thy, whereas they exhibit no apparent skin hypopigmentation and blood or immune system 
abnormalities (Figure 2).
The study included two patients in a Japanese consanguineous family (Figure 2). Neurologic 
examination was performed in two patients. Detailed clinical and laboratory findings of the 
two patients were shown in Table 1 and Figures 3 and 4. Blood examinations revealed perox-
idase-positive giant granules in granulocytes in two cases (Figure 4).
DNA analysis was done in two patients and two normal family members. We performed a 
genomewide linkage analysis employing SNP arrays with two patients’ DNAs (Figure 5A) 
and exome sequencing using one patient’s sample. We confirmed the mutation by Sanger 
sequencing of the family members (Figure 5B).
We identified a homozygous missense mutation (c.4189T>G, p.F1397V) in the lysosomal traf-
ficking regulator (LYST) gene in the two patients. (Figure 5B). This mutation co-segregated 
with the disease in the family and located at the well-conserved amino acid. (Figure 5C). 
We also detected a heterozygous nonsense mutation (c. 823C>T, p.R275X) in the BSCL2 gene 
in one patient (III-3), not in another one (III-1) (Figure 5C). BSCL2 is the causative gene for 
SPG17. This mutation is deleterious [26], and we suggest that this nonsense mutation is impli-
cated in phenotype differences between two cases: leg spasticity of III-3 is stronger than that 
of III-1.
Figure 2. Family pedigree with LYST gene mutation. The proband (III-3) and his older brother (III-1) show the almost 
same clinical phenotype. Other members are all healthy except for deceased elderly ones. The parents (II-1 and 2), who 
were first cousins, were neurologically asymptomatic. Arrow indicates the proband, and dots indicate the persons who 
permit analysis of their DNAs.
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The gene responsible for CHS was identified in 1996 and called lysosomal trafficking regulator 
(LYST) [27, 28]. The LYST gene is a large gene that has 51 coding exons and an open reading 
frame (ORF) of 11,403 kb [6]. The LYST protein, which is a large, putative cytosolic protein of 
III-1 III-3
Age at examination 63 53
Onset 58 48
Leg spasticity − +
Limb ataxia + +
Thigh muscle atrophy + +
Patellar Tendon Reflex (PTR) − ++
Achilles Tendon Reflex (ATR) + − −
Babinski sign + +
Vibration sense Normal Normal
Sphincter involvement − −
Mini-Mental State Examination (MMSE) 16/30 25/30
Lower limb NCV FWCV decreased Decreased
Sural nerve biopsy Axonal swelling, myelin↓ (Not examined)
Brain MRI Cerebellar atrophy Cerebellar atrophy
Spinal MRI Normal Thoracic atrophy
Large granules in granulocytes + +
Phagocytic activity of leukocytes 98.7% (Not examined)
NK-cell activity (18–40) 11 14
Table 1. Clinical and laboratory presentation of the two patients.
Figure 3. Brain and spinal MRI of the patient III-3. The brain MRI showed mild cerebellar atrophy, and spinal MRI 
disclosed mild thoracic cord atrophy.
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425 kDa (3801 amino acids), is ubiquitously expressed and involved in control of the exocy-
tosis of secretory lysosomes [28, 29]. The LYST protein has a BEACH (named after BEige And 
Chediak-Higashi) domain (amino acid numbers 3132–3422) [28], Trp-Asp (WD) 40 repeats 
(amino acid numbers 3477–3778), and a concanavalin (Con)A-like lectin domain (amino acid 
numbers 1390–1691) [30]. The LYST protein has been proposed to act as a scaffold protein 
in the mediation of fusion or a fission event of vesicles [31]. The mutation in this family 
(p.F1397V) is located within the ConA-like lectin domain. This domain could be involved 
in oligosaccharide binding associated with protein traffic and sorting along the secretory 
pathway [30].
Dysfunctional secretion of enlarged lysosome-related organelles, including lysosomes, mela-
nosomes, and cytolytic granules, has been observed in cells with mutations in LYST. Small 
interfering RNA knockdown of LYST in human cell lines replicates the LYST-mutant phe-
notype of large lysosomes [32]. They found no evidence that autophagy or endocytic deg-
radation was affected by LYST depletion. Autophagosomes are formed in normal size and 
volume and are able to form the large fused lysosomes, resulting in normal degradation rates. 
The large lysosomes are fully functioned in degrading endogenous proteins. LYST did not 
affect retrograde trafficking of toxins as well as the localization of transporters of lysosomal 
proteins, adaptor protein-3 (AP-3), and cation-independent mannose-6-phosphate recep-
tor (CI-MPR). The large lysosomes quantitative analysis demonstrates that LYST depletion 
results in reduction in vesicle content per cell; meanwhile, the total enzymatic amount and 
vesicular pH are unaffected, indicating a role for LYST in lysosomal fission and/or fusion 
events [32].
Figure 4. Peripheral blood leukocyte of patient III-3 (peroxidase stain). We found peroxidase-positive large granules 
in the patient’s granulocytes compared with normal control WBC. These patients had no symptoms according to 
immunodeficiency or bleeding tendency.
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Nevertheless, Drosophila with gene mutation of LYST homolog revealed impaired autophagy 
[33]. The roles of LYST in autophagy remain controversial [34].
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Figure 5. Linkage analysis and mutation of the lysosomal trafficking regulator (LYST) gene in the patients. (A) Linkage 
analysis. Linkage analysis involving SNPs revealed the highest LOD scores (about 1.8) in parts of chromosomes 1, 2, 
11, and 17 (arrows). These four areas were thought to be candidate areas in which the causative gene was located. (B) 
Sanger sequencing confirmed the homozygous nonsense mutation (c.4189T>G, p.F1397V) of the LYST gene identified 
in the proband (III-3) and the affected brother (III-1). This mutation co-segregated with the disease in this family. 
This LYST mutation was not found in 200 Japanese control DNAs. In one patient (III-3), we identified a heterozygous 
nonsense mutation (c.823C>T, p.R275*) of the BSCL2 gene, the causative one for SPG17, whereas no mutation in III-
1. (C) This mutation located at the highly conserved residues within the BEACH (named after BEige And Chediak-
Higashi) and concanavalin A (ConA)-like lectin domain.
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